[Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues].
OBJECTIVE
Cyclooxygenase-2 (COX-2) inhibitors have been shown to exert chemopreventive effects against gastrointestinal carcinomas. This study was to investigate the effect of celecoxib, a selective COX-2 inhibitor, on the expression of E-cadherin and serum levels of soluble E-cadherin in gastric carcinomas.


METHODS
Fifty-nine gastric carcinoma patients were randomly divided into two groups: surgery group (n=22) and celecoxib plus surgery group (n=37). Patients in the surgery group underwent surgical resection after diagnosis, while patients in the celecoxib plus surgery group received oral celecoxib, 200 mg twice daily for six days before curative resection. Twenty healthy subjects were recruited as normal controls. COX-2 and E-cadherin expressions were detected by immunohistochemistry. Serum levels of soluble E-cadherin were quantitatively measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.


RESULTS
Compared to the surgery group, the expression of COX-2 was significantly lower while that of E-cadherin was significantly higher in celecoxib plus surgery group. The concentrations of serum soluble E-cadherin before treatment were significantly higher in the surgery [(53.47+/-9.62) ng/mL] and the celecoxib plus surgery [(51.57+/-9.79) ng/mL] groups than in the control group [(37.17+/-5.38) ng/ml] (P<0.01). The soluble E-cadherin levels after surgery in both groups [(39.29+/-7.72) ng/mL and (29.29+/-8.28) ng/mL] were significantly lower than those before surgery (P<0.01). The soluble E-cadherin level on the sixth day [(44.11+/-8.36) ng/mL] was significantly lower than that before treatment in the celecoxib plus surgery group (P<0.01).


CONCLUSIONS
Short-term preoperative treatment of celecoxib up-regulates the expression of E-cadherin in gastric carcinomas.
Ran
Jun-Tao
JT
Department of Gastroenterology, The First Hospital Affiliated Lanzhou University, Lanzhou, Gansu, 730000, PR China.
Zhou
Yong-Ning
YN
Tang
Cheng-Wei
CW
Li
Hong-Hua
HH
Li
Xing-Wen
XW
Lu
Hong
H
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D000328:Adult; D015820:Cadherins / Q000097:blood / Q000378:metabolism*; D000068579:Celecoxib; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D057234:Preoperative Period; D011720:Pyrazoles / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D013449:Sulfonamides / Q000627:therapeutic use*; D015854:Up-Regulation
D015820:Cadherins; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D000068579:Celecoxib